Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).

Minang JT, Inglefield JR, Harris AM, Lathey JL, Alleva DG, Sweeney DL, Hopkins RJ, Lacy MJ, Bernton EW.

Vaccine. 2014 Nov 28;32(50):6847-54. doi: 10.1016/j.vaccine.2014.01.096. Epub 2014 Feb 13.

2.

Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.

Tierney C, Lathey JL, Christopherson C, Bettendorf DM, D'Aquila RT, Hammer SM, Katzenstein DA.

J Infect Dis. 2003 Jan 1;187(1):144-8. Epub 2002 Dec 13.

PMID:
12508159
3.

Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.

Klencke B, Matijevic M, Urban RG, Lathey JL, Hedley ML, Berry M, Thatcher J, Weinberg V, Wilson J, Darragh T, Jay N, Da Costa M, Palefsky JM.

Clin Cancer Res. 2002 May;8(5):1028-37.

4.

Effect of contaminating red blood cells on OKT3-mediated polyclonal activation of peripheral blood mononuclear cells.

Song S, Goodwin J, Zhang J, Babbitt B, Lathey JL.

Clin Diagn Lab Immunol. 2002 May;9(3):708-12.

5.

Comparison of human immunodeficiency virus antigens as stimulants for lymphocyte proliferation assays.

Schmitz JL, Denny TN, Garcia A, Lathey JL; Adult and Pediatric AIDS Clinical Trials Group Immunology Laboratory Subcommittees.

Clin Diagn Lab Immunol. 2002 May;9(3):525-9.

6.

Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.

Lathey JL, Tierney C, Chang SY, D'Aquila RT, Bettendorf DM, Alexander HC, Santini CD, Hughes AM, Barroga CF, Spector SA, Landes JE, Hammer SM, Katzenstein DA.

J Infect Dis. 2001 Dec 1;184(11):1402-11. Epub 2001 Nov 13.

PMID:
11709782
7.

Co-receptor usage was more predictive than NSI/SI phenotype for HIV replication in macrophages: is NSI/SI phenotyping sufficient?

Lathey JL, Brambilla D, Goodenow MM, Nokta M, Rasheed S, Siwak EB, Bremer JW, Huang DD, Yi Y, Reichelderfer PS, Collman RG.

J Leukoc Biol. 2000 Sep;68(3):324-30.

PMID:
10985247
8.

Need for an external proficiency testing program for cytokines, chemokines, and plasma markers of immune activation.

Fahey JL, Aziz N, Spritzler J, Plaeger S, Nishanian P, Lathey JL, Seigel J, Landay AL, Kilarui R, Schmitz JL, White C, Wara DW, Akridge R, Cutili J, Douglas SD, Reuben J, Shearer WT, Nokta M, Polland R, Schooley R, Asthana D, Mizrachi Y, Waxdal M.

Clin Diagn Lab Immunol. 2000 Jul;7(4):540-8.

9.

Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine.

Viani RM, Gutteberg TJ, Lathey JL, Spector SA.

AIDS. 1999 Jul 9;13(10):1273-4. No abstract available.

PMID:
10416533
10.
11.
12.

Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.

Fiscus SA, Hughes MD, Lathey JL, Pi T, Jackson B, Rasheed S, Elbeik T, Reichman R, Japour A, Byington R, Scott W, Griffith BP, Katzenstein DA, Hammer SM.

J Infect Dis. 1998 Mar;177(3):625-33.

PMID:
9498441
13.

Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.

Lathey JL, Hughes MD, Fiscus SA, Pi T, Jackson JB, Rasheed S, Elbeik T, Reichman R, Japour A, D'Aquila RT, Scott W, Griffith BP, Hammer SM, Katzenstein DA.

J Infect Dis. 1998 Mar;177(3):617-24.

PMID:
9498440
14.

Human cytomegalovirus-associated immunosuppression is mediated through interferon-alpha.

Noraz N, Lathey JL, Spector SA.

Blood. 1997 Apr 1;89(7):2443-52.

15.

Deterioration of detectable human immunodeficiency virus serum p24 antigen in samples stored for batch testing.

Lathey JL, Marschner IC, Kabat B, Spector SA.

J Clin Microbiol. 1997 Mar;35(3):631-5.

16.
18.
19.

Length of incubation time for human immunodeficiency virus cultures.

Fiscus SA, Welles SL, Spector SA, Lathey JL.

J Clin Microbiol. 1995 Jan;33(1):246-7.

20.
21.

Dysregulation of cytokine expression in monocytes from HIV-positive individuals.

Lathey JL, Kanangat S, Rouse BT, Agosti JM, Spector SA.

J Leukoc Biol. 1994 Sep;56(3):347-52.

PMID:
8083606
22.
24.

A defect in tissue factor expression in monocytes from patients infected by HIV correlates with markers of disease progression.

Lathey JL, Agosti JM, Spector SD.

AIDS. 1992 Dec;6(12):1542-4. No abstract available.

PMID:
1362881
25.
26.

Cultured human brain capillary endothelial cells are permissive for infection by human cytomegalovirus.

Lathey JL, Wiley CA, Verity MA, Nelson JA.

Virology. 1990 May;176(1):266-73.

PMID:
2158692
27.

A selective defect in tissue factor mRNA expression in monocytes from AIDS patients.

Lathey JL, Agosti JM, Nelson JA, Corey L, Gregory SA, Morrissey JH, Edgington TS, Oldstone MB.

Clin Immunol Immunopathol. 1990 Jan;54(1):1-13.

PMID:
2293902
30.
31.
32.
34.
35.

Inadvertent intravenous administration of trivalent influenza vaccine. Confusion of vaccine cartridge with heparin flush cartridge.

Van Voris LP, Shaffer JL, Lathey JL.

JAMA. 1981 Jun 19;245(23):2422-3. No abstract available.

PMID:
7230474

Supplemental Content

Loading ...
Support Center